Latest Insider Transactions at Alector, Inc. (ALEC)
This section provides a real-time view of insider transactions for Alector, Inc. (ALEC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alector, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alector, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,175
+3.21%
|
$172,575
$9.15 P/Share
|
|
Jun 02
2021
|
Calvin Yu Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,844
-1.43%
|
$31,348
$17.77 P/Share
|
|
May 21
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,975
-5.19%
|
$269,550
$18.14 P/Share
|
|
May 21
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,975
+2.48%
|
$134,775
$9.15 P/Share
|
|
May 18
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,200
-1.51%
|
$75,600
$18.04 P/Share
|
|
May 18
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,200
+0.75%
|
$37,800
$9.15 P/Share
|
|
May 07
2021
|
Arnon Rosenthal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+9.34%
|
-
|
|
May 07
2021
|
Shehnaaz Suliman President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
May 07
2021
|
Robert King Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+7.93%
|
-
|
|
May 07
2021
|
Robert Paul Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+17.98%
|
-
|
|
May 07
2021
|
Calvin Yu Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+11.21%
|
-
|
|
Apr 07
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,300
-4.73%
|
$423,700
$19.51 P/Share
|
|
Apr 07
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,300
+3.03%
|
$245,300
$11.82 P/Share
|
|
Mar 23
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,800
-6.07%
|
$303,600
$22.21 P/Share
|
|
Mar 23
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,800
+5.72%
|
$110,400
$8.16 P/Share
|
|
Mar 22
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,000
-6.28%
|
$690,000
$23.2 P/Share
|
|
Mar 22
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.96%
|
$240,000
$8.16 P/Share
|
|
Mar 09
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,175
-8.23%
|
$345,150
$18.12 P/Share
|
|
Mar 09
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,175
+3.89%
|
$172,575
$9.15 P/Share
|
|
Feb 09
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,175
-8.23%
|
$383,500
$20.81 P/Share
|
|
Feb 09
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,175
+3.89%
|
$172,575
$9.15 P/Share
|
|
Jan 26
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
27,308
-11.33%
|
$491,544
$18.0 P/Share
|
|
Jan 26
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,308
+5.3%
|
$245,772
$9.15 P/Share
|
|
Jan 25
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,000
-12.31%
|
$540,000
$18.01 P/Share
|
|
Jan 25
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.6%
|
$270,000
$9.15 P/Share
|
|
Jan 20
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,567
-3.85%
|
$154,206
$18.0 P/Share
|
|
Jan 20
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,567
+1.89%
|
$77,103
$9.15 P/Share
|
|
Jan 19
2021
|
Robert Paul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,000
-12.31%
|
$540,000
$18.12 P/Share
|
|
Jan 19
2021
|
Robert Paul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.6%
|
$270,000
$9.15 P/Share
|
|
Apr 16
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
62,183
-0.78%
|
$1,430,209
$23.53 P/Share
|
|
Apr 14
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,231
-0.29%
|
$534,313
$23.52 P/Share
|
|
Apr 09
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
288,101
-3.5%
|
$6,626,323
$23.79 P/Share
|
|
Apr 08
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
82,614
-0.99%
|
$1,900,122
$23.65 P/Share
|
|
Apr 07
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,170
-0.11%
|
$210,910
$23.1 P/Share
|
|
Mar 31
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
250,000
-2.91%
|
$6,000,000
$24.5 P/Share
|
|
Mar 25
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
56,411
-0.65%
|
$1,353,864
$24.66 P/Share
|
|
Mar 24
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
67,644
-0.78%
|
$1,623,456
$24.45 P/Share
|
|
Mar 23
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
14,598
-0.17%
|
$379,548
$26.05 P/Share
|
|
Mar 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,874,203
-44.93%
|
$48,729,278
$26.0 P/Share
|
|
Jan 09
2020
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
379,997
-3.46%
|
$7,219,943
$19.5 P/Share
|
|
Dec 26
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,800
-1.02%
|
$194,400
$18.6 P/Share
|
|
Dec 24
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
71,800
-5.78%
|
$1,364,200
$19.59 P/Share
|
|
Dec 23
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
94,285
-6.3%
|
$1,791,415
$19.82 P/Share
|
|
Dec 20
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
342,500
-14.71%
|
$6,507,500
$19.66 P/Share
|
|
Dec 17
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
954,100
-21.93%
|
$17,173,800
$18.52 P/Share
|
|
Aug 07
2019
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
650,000
-5.04%
|
$11,050,000
$17.9 P/Share
|
|
Feb 11
2019
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
411,700
+17.84%
|
$7,822,300
$19.0 P/Share
|
|
Feb 11
2019
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
12,682,329
+25.55%
|
-
|